Phase 3 Results for Ixekizumab Promising in Patients with Non-Radiographic Axial Spondyloarthritis

The frequency of adverse events and serious adverse events, including those that led to therapy discontinuation, was low and similar across all study groups. No new safety signals were identified.

This study showed that adding ixekizumab to conventional background medications was superior to conventional background medication alone for improving the signs, symptoms and inflammation on MRI in patients with non-radiographic axSpA.

Michele B. Kaufman, PharmD, BCGP, is a freelance medical writer based in New York City and a pharmacist at New York Presbyterian Lower Manhattan Hospital.

Reference

Deodhar A, van der Heijde D, Gensler L, et al. Ixekizumab in non-radiographic axial spondyloarthritis: Primary results from a phase 3 trial [abstract #2729]. Arthritis Rheumatol. 2019 Oct; 71(suppl 10).

Over the past few years, biosimilars and other new drugs have been introduced to treat rheumatic illnesses. Some of the conditions we treat have numerous drug options; others have few or only off-label options. This series, Rheumatology Drugs at a Glance, provides streamlined information on the administration of biologic, biosimilar and other medications used to…

PHILADELPHIA—Approximately 100 research abstracts on axial spondyloarthritis (axSpA) were accepted for presentation at ACR Convergence 2022. It is exciting to see a wealth of research on axSpA being undertaken worldwide. Here, we highlight important points from 10 of these studies. 1. Abstract 0378: Prevalence of Axial Spondyloarthritis (axSpA) in Patients Treated for Chronic Back Pain…

New research clarifies terminology used for diagnosis, but questions remain around epidemiology, genetics and management of patients with axial skeletal inflammation

The FDA has approved upadacitinib for the treatment of non-radiographic axial spondyloarthritis (nr-axSpA) based on a short-term study that demonstrated improved pain, function and other symptoms of nr-axSpA in patients with active disease.

Clinical Insights into Axial Spondyloarthritis: Rheumatology Drugs at a Glance, Part 5

Top Research in Axial Spondyloarthritis Presented at ACR Convergence 2022

Rheumatologists Make Progress Defining Spectrum of Axial Spondyloarthritis

FDA Approves Upadacitinib for Non-Radiographic Axial Spondyloarthritis

Related Articles